Serina Therapeutics, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $130,000 | $56,000 | $3.2M | $34,000 | $144,000 |
| Gross profit | — | — | $102,000 | $21,000 | $125,000 |
| Operating income | -$24.0M | -$17.0M | -$3.1M | -$7.0M | -$7.9M |
| Operating expenses | $24.2M | $17.1M | $6.3M | $7.0M | $8.2M |
| Cost of revenue | — | — | $40,000 | $13,000 | $19,000 |
| Cash from operations | -$18.0M | -$17.1M | -$2.5M | -$5.9M | -$7.9M |
| Capital expenditure | $59,000 | $22,000 | $504,000 | — | — |
| Free cash flow | -$18.0M | -$17.2M | -$3.0M | — | — |
| Impairments | $0 | $0 | $0 | — | — |
| Total assets | $7.0M | $6.7M | $9.0M | $3.2M | $3.2M |
| Total liabilities | $7.0M | $6.2M | $4.9M | $20.6M | $15.0M |
| Total debt | — | — | — | $21.4M | $14.7M |
Shares outstanding 15.0M · Free float 38.9%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.